|Mr. Brenton L. Saunders J.D.||Chairman, Chief Exec. Officer and Pres||4.14M||N/A||47|
|Ms. Maria Teresa Hilado||Exec. VP & CFO||1.26M||N/A||52|
|Mr. Robert A. Stewart||Exec. VP & Chief Operating Officer||1.49M||N/A||49|
|Mr. William Meury||Chief Commercial Officer and Exec. VP||1.69M||936.88k||49|
|Mr. James C. D'Arecca||Chief Accounting Officer and VP||N/A||N/A||46|
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womens health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimers disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Allergan plc’s ISS Governance QualityScore as of October 15, 2017 is 8. The pillar scores are Audit: 10; Board: 2; Shareholder Rights: 7; Compensation: 8.